Starpharma Holdings Ltd
ASX:SPL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Starpharma Holdings Ltd
ASX:SPL
|
AU |
|
Patterson Companies Inc
NASDAQ:PDCO
|
US |
|
Befesa SA
XETRA:BFSA
|
LU |
|
Novogene Co Ltd
SSE:688315
|
CN |
|
Lindab International AB
STO:LIAB
|
SE |
|
Valuence Merger Corp I
NASDAQ:VMCA
|
US |
|
Gozde Girisim Sermayesi Yatirim Ortakligi AS
IST:GOZDE.E
|
TR |
|
Cochlear Ltd
ASX:COH
|
AU |
|
Joeone Co Ltd
SSE:601566
|
CN |
|
Viva Goods Co Ltd
HKEX:933
|
HK |
|
Elisa Oyj
OMXH:ELISA
|
FI |
|
E
|
Econach Holdings Co Ltd
TSE:3521
|
JP |
|
Valartis Group AG
SIX:VLRT
|
CH |
|
Epsilon Healthcare Ltd
OTC:HDRPF
|
AU |
Starpharma Holdings Ltd
Starpharma Holdings Ltd. engages in the research and development of dendrimer products for pharmaceutical, life science and other applications. The company is headquartered in Melbourne, Victoria and currently employs 50 full-time employees. The company went IPO on 2000-09-28. The firm is engaged in development of dendrimer products for pharmaceutical, life science and other applications. The firm has two core development programs: VivaGel portfolio and Dendrimer Enhanced Product (DEP) drug delivery. VivaGel BV for bacterial vaginosis (BV) is a women’s health product. The company is available for sale under the brand names, Betafem BV Gel (UK), Betadine BV (Europe), Betadine BV Gel (Asia) and Fleurstat BVgel (Australia and New Zealand). DEP is a drug delivery platform, which provides demonstrated reproducible preclinical benefits across various internal and partnered DEP programs, including improved efficacy, safety, and survival. The firm has three internal DEP products includes DEP docetaxel, DEP cabazitaxel and DEP irinotecan. These internal DEP Products are in clinical development. The firm develops several products internally and others via commercial partnerships.
Starpharma Holdings Ltd. engages in the research and development of dendrimer products for pharmaceutical, life science and other applications. The company is headquartered in Melbourne, Victoria and currently employs 50 full-time employees. The company went IPO on 2000-09-28. The firm is engaged in development of dendrimer products for pharmaceutical, life science and other applications. The firm has two core development programs: VivaGel portfolio and Dendrimer Enhanced Product (DEP) drug delivery. VivaGel BV for bacterial vaginosis (BV) is a women’s health product. The company is available for sale under the brand names, Betafem BV Gel (UK), Betadine BV (Europe), Betadine BV Gel (Asia) and Fleurstat BVgel (Australia and New Zealand). DEP is a drug delivery platform, which provides demonstrated reproducible preclinical benefits across various internal and partnered DEP programs, including improved efficacy, safety, and survival. The firm has three internal DEP products includes DEP docetaxel, DEP cabazitaxel and DEP irinotecan. These internal DEP Products are in clinical development. The firm develops several products internally and others via commercial partnerships.
